These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 18188524

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Sorafenib and sunitinib.
    Kim A, Balis FM, Widemann BC.
    Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T.
    Nihon Jinzo Gakkai Shi; 2012 Aug; 54(5):574-80. PubMed ID: 22991835
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ.
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [Abstract] [Full Text] [Related]

  • 31. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
    Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G.
    Nat Rev Clin Oncol; 2009 Apr; 6(4):219-28. PubMed ID: 19333228
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
    Guevremont C, Alasker A, Karakiewicz PI.
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):170-9. PubMed ID: 19528803
    [Abstract] [Full Text] [Related]

  • 37. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Zambelli A, Della Porta MG, Eleuteri E, De Giuli L, Catalano O, Tondini C, Riccardi A.
    Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Deslandres M, Sibaud V, Chevreau C, Delord JP.
    Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
    [Abstract] [Full Text] [Related]

  • 40. [Dermatologic side effects induced by new angiogenesis inhibitors].
    Sibaud V, Garrido-Stowhas I, Cottura E, Chevreau C.
    Bull Cancer; 2011 Oct; 98(10):1221-9. PubMed ID: 22001771
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.